Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
== Knockout and functional evidence == The signaling molecule Wnt7-a is expressed within the female embryo, controlling the proper establishment of the uterus and the anterior-posterior axis within the female reproductive tract. Prenatal knockout of the Wnt7-a gene disrupts the early stages of the female reproductive tract, resulting in the lack of a comprehensive analysis of the gene’s role in development. However, a conditional knockout of the gene after birth, provided greater insight into the role of the gene in terms of uterine development. Initial appearance between the control mice and mutant mice appear similar, as both models presented with a vagina, cervix, oviduct, and ovary. In postnatal development, the Wnt7-a-null mice failed to develop endometrial glands and lacked the expression of genes Foxa2, Hoxa10, Hoxa11, Msx1, and Wnt16. The lack of endometrial glands within the mice resulted in infertility, as blastocyst failed to implant in the immature uterus. Loss of Wnt7-a during prenatal development results in absence of normal female anatomy and infertility while loss of Wnt7-a during postnatal development results in the presence of normal female anatomy and infertility.
Concentrations of taste buds vary from species to species, with bullhead catfish having 25 buds in a square millimeter of barbel skin. Barbels begin to develop during the embryonic, larval, or juvenile life stages of most of the species in which they are present. Development regulation of barbels has been linked to the C-C motif ligand 33 of the chemokine family of genes, due to its presence in barbeled catfish and zebrafish and absence or difference in expression in barbel-less members of the same families. This class of genes are signalling genes that provide migrating cells directional information during morphogenesis.
However, Chaz Williams has disputed those accounts, stating that although the confrontation became physical, neither man was injured and both parties ultimately walked away without a scratch. Another incident took place at The Hit Factory a month later: As 50 Cent and members of G-Unit were recording upstairs, while Ja Rule and members of Murder Inc. were downstairs in another studio section. The two crews later discovered their proximity, and a fight later ensued. In the midst of the brawl, Murder Inc. affiliate Black Child stabbed several combatants, including 50 Cent. Despite being formally charged, Black Child claimed self-defense in the incident, and was later acquitted of any charges following the stabbing. Tensions continued to further escalate for 50 Cent following the studio brawl, as he had still maintained ties to numerous drug kingpins around Queens.
== Variations == In addition to performing the reaction in a variety of organic solvents, conditions have been devised which allow for a broad range of Stille couplings in aqueous solvent. In the presence of Cu(I) salts, palladium-on-carbon has been shown to be an effective catalyst. In the realm of green chemistry a Stille reaction is reported taking place in a low melting and highly polar mixture of a sugar such as mannitol, a urea such as dimethylurea and a salt such as ammonium chloride. The catalyst system is tris(dibenzylideneacetone)dipalladium(0) with triphenylarsine:
==== Absorption ==== Peak plasma concentration (Cmax) of alvimopan is reached approximately 2 hours after oral dosing, while the Cmax for metabolite occurs 36 hours after an oral dose. Alvimopan's high affinity for the peripheral μ-receptor results in an absolute bioavailability less than 7%.
Sources: en.wikipedia.org
A collection of reprints of notable reviews from the magazine's history, along with retrospective commentary on each game. In addition to reviews of popular titles (including the three "ten out of ten" scores that had been awarded during that period), it also included Edge's comments on notable hyped disappointments such as Rise of the Robots and Daikatana. The issue also included an index of the content of those 100 issues of the magazine. "Retro: The guide to classic videogame playing and collecting" (2002)
=== Regulatory status === Selegiline is a prescription drug. It is not specifically a controlled substance in the United States and hence is not an illegal drug. However, deprenyl and selegiline are controlled substances in Japan. They are classified as "Stimulants", alongside a variety of other amphetamines, under Article 2 of Japan's Narcotics and Psychotropics Control Law. Selegiline is known to metabolize into small amounts of levoamphetamine and levomethamphetamine but is thought to have little to no misuse potential or dependence liability.
=== September === 4 September – The ESA/JAXA BepiColombo mission performs the closest ever flyby of a planet, as it speeds past Mercury at a distance of just 165 km (103 mi). 10 September – Researchers in Sweden demonstrate a battery made of carbon fibre composite as stiff as aluminium and energy-dense enough to be used commercially. 11 September A study finds that the bluestreak cleaner wrasse (Labroides dimidiatus), a small tropical fish, may possess a form of self-awareness. The Jülich Supercomputing Centre in Germany announces the start of installation for JUPITER, Europe's first exascale supercomputer. 12 September OpenAI releases its "o1" series of large language models (LLMs), featuring improved capabilities in coding, math, science and other complex tasks. Jared Isaacman and Sarah Gillis complete the first commercial spacewalk and test slimmed-down spacesuits designed by SpaceX. A study suggests Earth had planetary rings during the Ordovician period, formed from the breakup of an asteroid, from which material deorbited during the ~40 million years long Ordovician meteor event ~466 million years ago, resulting in an otherwise unlikely crater distribution. A policy study finds bans of food waste disposals in landfills, which produce very large amounts of greenhouse gases, in five U.S. states had almost no effect with the exception of the state of Massachusetts. It suggests several makings that may have contributed to that states' success.
Cl2C=CHCl + KH → ClC≡CCl + KCl + H2 A trace of methanol is required. It has also been generated (and used in situ) using lithium diisopropylamide under anhydrous conditions as well as potassium hydroxide.
Sources: en.wikipedia.org
== Composition == Bacitracin is composed of a mixture of related compounds with varying degrees of antibacterial activity. Notable fractions include bacitracin A, A1, B, B1, B2, C, D, E, F, G, and X. Bacitracin A has been found to have the most antibacterial activity. Bacitracin B1 and B2 have similar potencies and are approximately 90% as active as bacitracin A.
Fibronectin is a high molecular weight (approximately 500–600 kDa) glycoprotein of the extracellular matrix that binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans (e.g. syndecans). Fibronectin exists as a protein dimer, consisting of two nearly identical monomers linked by a pair of disulfide bonds. The fibronectin protein is produced from a single gene, but alternative splicing of its pre-mRNA leads to the creation of several isoforms. Two types of fibronectin are present in vertebrates:
== Personal life == Townsend was born in Leytonstone, Greater London. He is the son of Troy Townsend, Head of Development for Kick It Out. He is of paternal Jamaican and maternal Greek Cypriot descent. He was brought up in Chingford, and is a lifelong Tottenham fan. He attended Rush Croft Sports College. When Townsend was 10, his half-brother Kurtis died in a car accident, aged 18. One of his cousins is Colin Kazim-Richards, also a professional footballer. Townsend was filmed singing the song "Stand By Me" by Ben E. King with the rest of the Tottenham youth players in the dressing room, which became a popular internet video. Townsend said in a December 2019 interview that he had been a problem gambler, compulsively betting online on football. He lost £46,000 on a single bet in 2012 on the night before a play-off game for Birmingham. After being caught for breaking the FA's anti-betting rules, he went to counselling. In November 2023, while on a short-term contract with Luton Town, Townsend said he was trying to improve his fitness and prolong his career. He highlighted his consumption of chicken feet, which are high in collagen as a boost to his overall fitness. Townsend worked as a pundit and co-commentator for ITV during the 2022 World Cup, Euro 2024 and 2026 World Cup. In May 2026, Townsend posted a social media video questioning why people needed to wear sunglasses to protect their eyes from sunlight but not from artificial light.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.